Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 2/20 | 0.41 |
| ▸ | KRAS | P01116 | 3/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | FUT6 | P51993 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636126 | 0.94 | HINT1 (0.50) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL17955416 | 0.93 | ADORA3 (0.41) | HINT1TAS1R3TAS1R1NT5EADORA3 | |
| SCHEMBL17232119 | 0.88 | HINT1 (0.49) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL18636353 | 0.87 | NT5E (0.41) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL12202712 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL12758246 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL3132403 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL10819846 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL13522420 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS | |
| SCHEMBL16350180 | 0.86 | HINT1 (0.45) | HINT1TAS1R3TAS1R1NT5EKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755983-B1 | SUBSTITUTED CARBONYLOXYMETHYLPHOSPHORAMIDATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | HINT1 1267/4885TAS1R3 4769/4885TAS1R1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.